Spots Global Cancer Trial Database for A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
Official Title: An Open, 3-cohort, Phase II Trial Testing Oral Administration of Lucitanib in Patients With FGFR1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
Study ID: NCT02053636
Conditions
Interventions
Study Description
Brief Summary: The aim of the study is to evaluate the objective response rate (ORR) of single agent lucitanib in metastatic breast cancer patients with FGFR1-amplified, FGFR1-non amplified with 11q amplification, or FGFR1-non amplified without 11q amplification.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Peter MacCallum Cancer Centre, East Melbourne, , Australia
Westmead Hospital, Westmead, , Australia
Institut Jules Bordet, Brussels, , Belgium
Cliniques Universitaires St. Luc Oncology - Breast Clinic, Bruxelles, , Belgium
Grand Hôpital de Charleroi Oncologie-Hématologie, Charleroi, , Belgium
UZ Leuven Campus Gasthuisberg Dept. of General Medical, Leuven, , Belgium
Clinique Sainte-Elisabeth Médecine Interne - Oncologie, Namur, , Belgium
McGill University Department of Oncologie - Clinical Reserach Program, Montreal, , Canada
Princess Margaret Cancer Centre, Toronto, , Canada
University Health Network - Princess Margaret Hospital, Toronto, , Canada
Institut Claudius Regaud Dpt d'Oncologie Médicale, Toulouse, , France
Institut Gustave Roussy, Villejuif Cedex, , France
Institut Gustave Roussy Dépt d'oncologie - Cancer du sein, Villejuif, , France
Kliniken Essen-Mitte Klinik für Senologie - Brustzentrum, Essen, , Germany
KLINIKUM OFFENBACH Klinik für Gynäkologie und Geburtshilfe, Offenbach, , Germany
Klinikum Offenbach, Offenbach, , Germany
Orszagos Onkologiai Intezet Kemoterapia B es Klin.Farm.Oszt., Budapest, , Hungary
Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum Onkologiai Intezet, Debrecen, , Hungary
Istituto Europeo di Oncologia Divisione Sviluppo Nuovi Farmaci per Terapie Innovative, Milano, , Italy
Istituto Europeo di Oncologia, Milan, , Italy
H. Valle de Hebrón Servicio de Oncología, Barcelona, , Spain
Hospital Universitario Val d'Hebròn, Madrid, , Spain
MD Anderson Cancer Center Unidad de Investigación Clínica, Madrid, , Spain
H. Ramón y Cajal Servicio de Oncología Médica, Madrid, , Spain
H. Clínico de Valencia Servicio de Hematología y oncología Médica, Valencia, , Spain
Western General Hospital Edinburgh Cancer Centre, Edinburgh, , United Kingdom
Royal Marsden Hospital, London, , United Kingdom
The Royal Marsden NHS Trust Dpt of Medicine-Oncology, London, , United Kingdom
Nottingham University Hospitals NHS Trust Department of Clinical Oncology, Nottingham, , United Kingdom
Contact Details
Name: Fabrice André, MD
Affiliation: Institut Gustave Roussy, France
Role: STUDY_CHAIR
Name: Javier Cortes, MD
Affiliation: Hospital Universitario Vall d'Hebrón, Spain
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
